Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects

Ciprero, Karen L.; Zykov, K. A.; Брико, Н. И.; Shekar, Tulin; Sterling, Tina; Bitieva, Elizaveta; Stek, Jon E.; Musey, Luwy

doi:10.1080/21645515.2016.1165373

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For persons ≥ 2 years of age, numerous studies have shown that PPV23 is effective in preventing IPD. Recent studies from Russia, 21 China 22 and Japan 23 demonstrated that geometric mean antibody titers (GMTs) to all tested serotypes increased dramatically after PPV23 vaccination. High proportions of subjects had ≥2-fold increases in IgG antibodies; for example, rates for serotypes 1, 6B, 14, 19F, and 23F were 92%, 83%, 89%, 81%, 84%, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…High proportions of subjects had ≥2-fold increases in IgG antibodies; for example, rates for serotypes 1, 6B, 14, 19F, and 23F were 92%, 83%, 89%, 81%, 84%, respectively. 21 Opsonophagocytic assay (OPA) GMTs also increased significantly, ranging from 8.2 to 65.4 23 . (See Table 2 for recent clinical trials concerning PPV23 vaccination in healthy populations).…”

Section: Introductionmentioning

confidence: 99%

“… Author/Reference Country year vaccine Study Population Treatment Key Findings Ciprero K et al. 21 Russia 2016 PNEUMOVAX™ 23 (Merck) Russian Federation who were either 2 to 49 years of age with increased risk for PD or ≥ 50 years Single dose of PPV23 High proportion of subjects had ≥2-fold increase in IgG following receipt of PPV23. Rates of which were 92.0%, 83.0%, 89.0%, 81%, 84% for serotypes 1, 6B, 14, 19F, and 23F, respectively Jong Gyun Ahn et al.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people ≥ 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The use of pneumococcal vaccinations against pneumonia is widespread (74–78). Furthermore, due to its long practice in the clinic, many optimizations of the vaccine have taken place, guaranteeing its safety even in vulnerable individuals such as pregnant women, young children, and the elderly (75–77). It should be noted that different S. pneumoniae strains as well as other bacteria, possess the phosphorylcholine epitope that triggers the production of anti-oxLDL IgM autoantibodies by means of molecular mimicry (31, 79).…”

Section: Discussionmentioning

confidence: 99%

Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease

et al. 2019

View full text Add to dashboard Cite

Niemann-Pick type C1 (NPC1) disease is caused by a deleterious mutation in the Npc1 gene, causing lysosomal accumulation of unesterified cholesterol and sphingolipids. Consequently, NPC1 disease patients suffer from severe neurovisceral symptoms which, in the absence of effective treatments, result in premature death. NPC1 disease patients display increased plasma levels of cholesterol oxidation products such as those enriched in oxidized low-density lipoprotein (oxLDL), a pro-inflammatory mediator. While it has been shown that inflammation precedes and exacerbates symptom severity in NPC1 disease, it is unclear whether oxLDL contributes to NPC1 disease progression. In this study, we investigated the effects of increasing anti-oxLDL IgM autoantibodies on systemic and neurological symptoms in an NPC1 disease mouse model. For this purpose, Npc1nih mice were immunized with heat-inactivated S. pneumoniae, an immunogen which elicits an IgM autoantibody-mediated immune response against oxLDL. Npc1nih mice injected with heat-inactivated pneumococci displayed an improved hepatic phenotype, including liver lipid accumulation and inflammation. In addition, regression of motor skills was delayed in immunized Npc1nih. In line with these results, brain analyses showed an improved cerebellar phenotype and neuroinflammation in comparison with control-treated subjects. This study highlights the potential of the pneumococcal immunization as a novel therapeutical approach in NPC1 disease. Future research should investigate whether implementation of this therapy can improve life span and quality of life of NPC1 disease patients.

show abstract

“…The use of pneumococcal vaccinations against pneumonia is widespread (74-78). Furthermore, due to its long practice in the clinic, many optimizations of the vaccine have taken place, guaranteeing its safety even in vulnerable individuals such as pregnant women, young children and the elderly (75)(76)(77). It should be noted that different S. pneumoniae strains, as well as other bacteria, possess the phosphorylcholine epitope that triggers the production of anti-oxLDL IgM autoantibodies by means of molecular mimicry (31,79).…”

Section: Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms In A Mouse Model Formentioning

confidence: 99%

Mind the gatekeeper

Reis¹

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects

Abstract: PPV23 is generally safe, well tolerated, and highly immunogenic when given as a single dose to Russian individuals 50 y of age and older, as well as Russian individuals 2 to 49 y of age who are at high risk for PD.

Cited by 9 publications

References 29 publications

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease

Mind the gatekeeper

Contact Info

Product

Resources

About